This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05370885
Recruitment Status : Recruiting
First Posted : May 12, 2022
Last Update Posted : April 1, 2024
Sponsor:
Information provided by (Responsible Party):
Vedanta Biosciences, Inc.

Brief Summary:
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

Condition or disease Intervention/treatment Phase
Ulcerative Colitis Colitis, Ulcerative Biological: VE202 Drug: Vancomycin Oral Capsule Other: VE202 Placebo Other: Vancomycin Placebo Phase 2

Detailed Description:
A Phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate UC. In Parts 1 and 2 of the study, patients will receive VE202 or placebo for 8 weeks or 2 weeks. In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
Actual Study Start Date : May 8, 2023
Estimated Primary Completion Date : July 31, 2025
Estimated Study Completion Date : November 10, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.

In Part 1 of the study, patients in Group A will receive VE202 for 8 weeks.

In Part 2 of the study, patients in Group A will receive VE202 placebo for 2 weeks.

In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Biological: VE202
VE202 is a rationally defined, live biotherapeutic product for oral administration.

Drug: Vancomycin Oral Capsule
Vancomycin is an antibiotic used to treat or prevent infection

Other: VE202 Placebo
VE202 Placebo

Other: Vancomycin Placebo
Vancomycin Placebo

Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.

In Part 1 of the study, patients in Group B will receive VE202 placebo for 8 weeks.

In Part 2 of the study, patients in Group B will receive VE202 for 2 weeks.

In Part 3, patients will be followed for safety for 1 year from the start of treatment.

Biological: VE202
VE202 is a rationally defined, live biotherapeutic product for oral administration.

Drug: Vancomycin Oral Capsule
Vancomycin is an antibiotic used to treat or prevent infection

Other: VE202 Placebo
VE202 Placebo

Other: Vancomycin Placebo
Vancomycin Placebo




Primary Outcome Measures :
  1. Proportion of participants with endoscopic response on flexible sigmoidoscopy after 8 weeks of treatment with VE202 or placebo. [ Time Frame: 8 Weeks ]
    Endoscopic response is defined as a reduction from baseline of 1 point or more in Mayo endoscopic subscore. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.

  2. Percentage of participants with Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) that are treatment-related or Serious Adverse Events (SAEs) that are treatment-related in Part 1 and Part 2 of the study. [ Time Frame: 16 Weeks ]
    The safety of VE202 and placebo in Parts 1 and 2 of the study, which include an 8-week and 2-week course of treatment, respectively, will be evaluated.


Secondary Outcome Measures :
  1. Percentage of participants with endoscopic response on flexible sigmoidoscopy at Week 8, following treatment with VE202 for 2 weeks. [ Time Frame: 8 Weeks ]
    Endoscopic response is defined as a reduction from baseline of 1 point or more in Mayo endoscopic subscore. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.

  2. Number of participants with TEAEs, SAEs, and Adverse Events of Special Interest (AESIs) in Parts 1, 2, and 3 of the study. [ Time Frame: 52 Weeks ]
    The safety of VE202 and placebo in Parts 1, 2, and 3 of the study, which include an 8-week and 2-week course of treatment followed by a long-term follow-up period, will be evaluated. AESIs are defined as treatment-related Grade ≥2 TEAEs that are gastrointestinal or bacterial infections.

  3. Percentage of participants with clinical remission at Week 8 of Part 1 and Week 8 of Part 2. [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Clinical remission is defined as attaining a Mayo stool frequency subscore of ≤1 and an improvement in stool frequency subscore of ≥1 point from baseline, a rectal bleeding subscore of 0 and an endoscopic subscore ≤1. Each component of the Mayo score is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.

  4. Percentage of participants with clinical response at Week 8 of Part 1 and Week 8 of Part 2. [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Clinical response is defined as having met the definition of clinical remission or having a decrease from baseline of ≥2 points and a decrease of ≥30% in modified Mayo score, with either a rectal bleeding score of 0 or a decrease in rectal bleeding of ≥1 point. Each component of the modified Mayo score (stool frequency, rectal bleeding, endoscopy findings) is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.

  5. Percentage of participants with endoscopic remission on flexible sigmoidoscopy at Week 8 of Part 1 and Week 8 of Part 2. [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. Endoscopic response is defined as a Mayo endoscopic subscore of 0 or 1 point. The Mayo endoscopic subscore is evaluated on a scale of 0 to 3, with a higher score representing more severe disease.

  6. Change in Mayo score compared with baseline at Week 8 of Part 1 and Week 8 of Part 2. [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The Mayo score is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician global assessment), with each parameter evaluated on a scale of 0 to 3. The total score ranges from 0 to 12, and a higher score represents more severe disease.

  7. Histologic improvement at Week 8 of Part 1 and Week 8 of Part 2 as measured by Geboes score. [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The Geboes score encompasses 6 dimensions, each with 4 subcategories: architectural changes, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in the epithelium, crypt destruction, and erosions or ulcerations. The Geboes score ranges from grade 0 to 5.4. A higher Geboes score represents more severe disease.

  8. Histologic improvement at Week 8 of Part 1 and Week 8 of Part 2 as measured by the Robarts Histopathology Index (RHI). [ Time Frame: 8 Weeks ]
    Participants will receive 8 weeks of VE202/placebo in Part 1 and 2 weeks of VE202/placebo in Part 2. The RHI provides a score between 0 and 33, based on the levels of chronic inflammatory infiltrate, neutrophils in lamina propria and epithelium, and erosion/ulceration. A higher RHI score represents more severe disease.

  9. Change in fecal calprotectin levels after 2- and 8-week courses of VE202. [ Time Frame: 52 Weeks ]
    The change in fecal calprotectin level from baseline will be evaluated.

  10. Change in colonization with VE202 strains detected in feces at various time points in patients treated with 2- and 8-week courses of VE202. [ Time Frame: 52 Weeks ]
    VE202 colonization will be characterized in patients treated with 2- and 8-week courses of VE202.

  11. Change in the total percent of relative abundance of VE202 strains in feces at various time points in patients treated with 2- and 8-week courses of VE202. [ Time Frame: 52 Weeks ]
    VE202 colonization will be characterized in patients treated with 2- and 8-week courses of VE202.

  12. Change in taxonomic composition of gut microbiome in patients treated with 2- and 8-week courses of VE202. [ Time Frame: 52 Weeks ]
    Microbiome composition will be evaluated by measuring the sum of species and the genera or higher-level taxonomic groupings at baseline and at subsequent time points in patients treated with 2- and 8-week courses of VE202 or placebo.

  13. Change in fecal metabolite profiles at baseline and post-VE202 or placebo at various time points. [ Time Frame: 52 Weeks ]
    Short-chain fatty acid and bile acid concentrations will be evaluated at baseline and at subsequent time points in patients treated with 2- and 8-week courses of VE202 or placebo.

  14. Number of participants with hospitalization or surgical procedure related to UC after 2- and 8-week courses of VE202. [ Time Frame: 52 weeks ]
    To evaluate the impact of 2- and 8-week courses of VE202 on Inflammatory bowel disease (IBD) specific healthcare resource utilization.

  15. Change in patient-reported outcome measures using the Inflammatory Bowel Disease Questionnaire (IBDQ) to evaluate the impact of 2- and 8-week courses of VE202 IBD-specific health-related quality of life. [ Time Frame: 52 Weeks ]
    The 32-item IBDQ uses a 7-point scale to assess disease-specific health-related quality of life across 4 dimensions: bowel symptoms, systemic symptoms, emotional wellbeing, and social function. The total IBDQ score is calculated by adding the scores within each domain. Scores can range from 32 to 224, with a higher score indicating a better outcome.

  16. Change in patient-reported outcome measures using the EuroQoL-5D Health Assessment Questionnaire (EQ-5D) scores to evaluate the impact of 2- and 8-week courses of VE202 IBD-specific health-related quality of life. [ Time Frame: 52 Weeks ]
    The EuroQoL-5D Health Assessment Questionnaire (EQ-5D) is a standardized, self-administered, non-disease-specific instrument for measuring generic health status for routine clinical outcome measurement in the delivery of operational healthcare. Scores range from 0 to 100, with a higher score indicating better outcome.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

KEY INCLUSION CRITERIA

  1. 18 to 75 years of age
  2. Documented clinical and endoscopic diagnosis of UC at least 3 months prior to randomization
  3. Active mild to moderate UC, as defined by the following:

    1. Disease that extends at least 15 cm from the anal verge
    2. A modified Mayo score of 4 to 8 with: (i.) Mayo endoscopic subscore of ≥ 2 based on screening flexible sigmoidoscopy; (ii.) Rectal bleeding score of ≥ 1
  4. Has never received a biologic agent, Janus kinase inhibitor, or sphingosine-1-phosphate modulator for the treatment of UC
  5. If receiving corticosteroids, dose must be stable for at least 4 weeks before randomization
  6. Doses of other allowable UC medications must be stable for at least 8 weeks before randomization

KEY EXCLUSION CRITERIA

  1. Known history of Crohn's disease (CD) or indeterminate colitis
  2. A known diagnosis of primary sclerosing cholangitis
  3. Allergy to VE202 or any of its components
  4. Allergy to vancomycin or any of its components
  5. A diagnosis of any non-IBD diarrheal illness (eg, Clostridioides difficile, celiac disease, parasitic infection) within 3 months prior to randomization
  6. Use of probiotics or herbal, botanical, or traditional medicinal preparations within the 2 weeks prior to randomization (consumption of food products such as yogurt, kefir, kombucha, and herbal teas is permissible)
  7. Receipt of Fecal Microbiota Transplantation (FMT) or other fecal-derived preparation within 6 months prior to randomization
  8. Prior colectomy, ostomy, or other intestinal surgery (excluding cholecystectomy or appendectomy)
  9. Receipt of any investigational biologic within 60 days or 5 half-lives prior to randomization, whichever is longer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05370885


Contacts
Layout table for location contacts
Contact: Mary Garfield, MS 203.906.5693 Consortium02-ctinquiries@vedantabio.com
Contact: Azadeh Haghighi, MS Consortium02-ctinquiries@vedantabio.com

Locations
Show Show 53 study locations
Sponsors and Collaborators
Vedanta Biosciences, Inc.
Layout table for additonal information
Responsible Party: Vedanta Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT05370885    
Other Study ID Numbers: VE202-002
2021-001280-24 ( EudraCT Number )
First Posted: May 12, 2022    Key Record Dates
Last Update Posted: April 1, 2024
Last Verified: March 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Vedanta Biosciences, Inc.:
Ulcerative Colitis
VE202
Vedanta
Clostridia
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents